At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 292 enrolled
Drug / intervention
PF-06700841 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 CREAM APPLIED ONCE OR TWICE DAILY FOR 6 WEEKS IN PARTICIPANTS WITH MILD OR MODERATE ATOPIC DERMATITIS
In Brief
A Phase 2 clinical trial evaluating PF-06700841 and Vehicle (Placebo) for Atopic Dermatitis. Completed, enrolled 292 participants across 76 sites in 10 countries.
Detailed Summary
This study is being conducted to provide data on efficacy, safety, tolerability and PK of multiple topical formulation concentrations of PF-06700841 topical cream in the treatment of mild to moderate atopic dermatitis (AD). The study is intended to enable selection of the dose and dosing regimen (once daily \[QD\] vs twice daily \[BID\] application) for the future clinical development of topical PF-06700841.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, Bulgaria, Canada, Denmark, Germany, Hungary, Japan, Latvia, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartMay 2019
Primary CompletionMay 2020
TodayJul 2026
First PostedApr 4, 2019
Enrollment StartMay 13, 2019
Primary CompletionMay 7, 2020
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 7.2 years ago
Interventions
PF-06700841drug
PF-06700841 topical cream
Vehicle (Placebo)drug
Vehicle topical cream